@article{ef4e8c6b73ca4b289c166943678bf7f5,
title = "Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer: European Journal of Cancer",
abstract = "Background: Patients with cancer are at increased risk of complicated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but it is still unclear if the risk of mortality is influenced by cancer type or ongoing anti-cancer treatments. An interesting debate concerning the potential relationship between androgen deprivation therapy (ADT) and SARS-CoV-2 infection has recently been opened in the case of prostate cancer (PC), and the aim of this multi-centre cohort study was to investigate the incidence and outcomes of SARS-CoV-2 infection in patients with metastatic castration-resistant prostrate cancer (mCRPC). Patients and methods: We retrospectively reviewed the clinical records of patients with mCRPC who developed SARS-CoV-2 infection, and recorded their baseline clinical characteristics, their history of PC and SARS-CoV-2 infection, and their oncological status and treatment at the time of infection. The primary study end point was the death rate and the possible impact of the patients' PC-related history and treatments on mortality. Results: Thirty-four of the 1433 patients with mCRPC attending the participating centres (2.3%) developed SARS-CoV-2 infection, 22 (64.7%) of whom were hospitalised. Most of the patients were symptomatic, the most frequent symptoms being fever (70.6%), dyspnoea (61.8%), cough (52.9%) and fatigue (38.2%). After a median follow-up of 21 days (interquartile range: 13–41), 13 patients had died (38.2%), 17 recovered (50.0%) and four (11.7%) were still infected. The number of treatments previously administered for mCRPC had a significant impact on mortality (p = 0.004). Conclusions: Our findings contribute additional data to the current debate concerning the postulated protective role of ADT, which seems to be less in patients with metastatic PC. {\textcopyright} 2020 Elsevier Ltd",
keywords = "Androgen deprivation therapy, COVID-19, Metastatic castration-resistant prostate cancer, SARS-CoV-2 infection, abiraterone, cabazitaxel, docetaxel, enzalutamide, steroid, aged, Article, castration resistant prostate cancer, coronavirus disease 2019, coughing, dyspnea, fatigue, fever, human, incidence, major clinical study, male, medical history, medical record review, metastasis, mortality, priority journal, retrospective study, Betacoronavirus, bone tumor, complication, Coronavirus infection, follow up, isolation and purification, Italy, multimodality cancer therapy, pandemic, pathology, prognosis, survival rate, very elderly, virology, virus pneumonia, Aged, Aged, 80 and over, Bone Neoplasms, Combined Modality Therapy, Coronavirus Infections, Follow-Up Studies, Humans, Incidence, Male, Pandemics, Pneumonia, Viral, Prognosis, Prostatic Neoplasms, Castration-Resistant, Retrospective Studies, Survival Rate",
author = "O. Caffo and D. Gasparro and {Di Lorenzo}, G. and A.D. Volta and P. Guglielmini and P. Zucali and R. Bortolus and A. Cavo and G. Ceresoli and R. Chiari and G. Fornarini and L. Fratino and A. Iaculli and M. Maruzzo and C. Masini and F. Morelli and C. Mucciarini and G. Procopio and R. Sabbatini and E. Verri and S. Kinspergher and F. Maines and C. Messina and A. Veccia and M. Donini",
note = "Export Date: 2 March 2021 CODEN: EJCAE Correspondence Address: Caffo, O.; Medical Oncology Department, Largo Medaglie D'Oro, Italy; email: orazio.caffo@apss.tn.it Chemicals/CAS: abiraterone, 154229-19-3; cabazitaxel, 183133-96-2; docetaxel, 114977-28-5; enzalutamide, 915087-33-1 References: https://www.statista.com/page/covid-19-coronavirus, Coronavirus (COVID-19) disease pandemic – Statistics & facts. [Accessed on 6 June 2020]; Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China (2020) Lancet Oncol, 21, pp. 335-337; Kuderer, N.M., Choueiri, T.K., Shah, D.P., Shyr, Y., Rubinstein, S.M., Rivera, D.R., Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) Lancet, 395, pp. 1907-1918; Lee, L.Y.W., Cazier, J.B., Starkey, T., Turnbull, C.D., U.K.C.C.M.P. Team, Kerr, R., COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study (2020) Lancet, 21, pp. 1309-1316; Wambier, C.G., Goren, A., Vano-Galvan, S., Ramos, P.M., Ossimetha, A., Nau, G., Androgen sensitivity gateway to COVID-19 disease severity (2020) Drug Dev Res; Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor (2020) Cell, 181. , 271-280 e278; Lin, B., Ferguson, C., White, J.T., Wang, S., Vessella, R., True, L.D., Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2 (1999) Cancer Res, 59, pp. 4180-4184; Mostaghel, E.A., Page, S.T., Lin, D.W., Fazli, L., Coleman, I.M., True, L.D., Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer (2007) Cancer Res, 67, pp. 5033-5041; Montopoli, M., Zumerle, S., Vettor, R., Rugge, M., Zorzi, M., Catapano, C.V., Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532) (2020) Ann Oncol, 31, pp. 1040-1045; Desai, A., Sachdeva, S., Parekh, T., Desai, R., COVID-19 and cancer: lessons from a pooled meta-analysis (2020) JCO Global Oncol, 6, pp. 557-559; Horn, L., Whisenant, J.G., Torri, V., Huang, L.-C., Trama, A., Paz-Ares, L.G., Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): impact of type of cancer therapy and COVID therapy on survival (2020) J Clin Oncol, 38. , LBA111-LBA111; Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., Chen, R., Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China (2020) Ann Oncol, 31, pp. 894-901; Barlesi, F., Foulon, S., Bayle, A., Gachot, B., Pommeret, F., Willekens, C., Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments (2020) Proceedings of the 111th annual meeting of the American association for cancer research, , Abstract nr CT403; Sharifi, N., Ryan, C.J., Androgen hazards with COVID-19 (2020) Endocr Relat Canc, 27, pp. E1-E3; Patel, V.G., Zhong, X., Liaw, B., Tremblay, D., Tsao, C.K., Galsky, M.D., Does androgen deprivation therapy protect against severe complications from COVID-19? (2020) Ann Oncol, 31, pp. 1419-1420",
year = "2020",
doi = "10.1016/j.ejca.2020.09.018",
language = "English",
volume = "140",
pages = "140--146",
journal = "Eur. J. Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
}